文献速递帕金森病与运动障碍

RAB32 Ser71Arg与常染色体显性帕金森病:连锁、关联及功能分析

RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
PubMed 文献 · Lancet Neurol · 2024-04-10

研究对加拿大和突尼斯无已知遗传病因的家族性帕金森病先证者行全外显子测序,发现RAB32 c.213C>G(Ser71Arg)在三个家系共分离,并在多国病例对照及公共数据库中验证其与帕金森病显著关联(OR 13.17,95%CI 2.15-87.23,p=0.0055,I²=99.96%),体外实验示RAB32 Arg71激活LRRK2激酶。

要点

  • RAB32 Ser71Arg在三个常染色体显性帕金森病家系共分离(非参数连锁Z=1.95,p=0.03)。
  • 病例对照关联显著:OR 13.17,95%CI 2.15-87.23,p=0.0055,异质性I²=99.96%。
  • 携带者帕金森病发病年龄54.6岁(SD 12.75,范围31-81,n=16),三分之二有家族史。

核心结论

  • RAB32 Ser71Arg是帕金森病新的遗传风险因素,外显率降低。
  • 该变异见于多个族裔的帕金森病患者,且共享同一单倍型。
  • 体外实验显示RAB32 Arg71激活LRRK2激酶,提示遗传学上不同的家族性帕金森病共享同一机制。

研究设计与样本

  • 研究对来自加拿大和突尼斯的130例无遗传病因的家族性帕金森病先证者行全外显子测序。
  • 对61个RAB GTP酶基因进行遗传筛查,并在先证者亲属中行连锁分析以评估疾病共分离。
  • 对2604例无关的特发性帕金森病患者和344例年龄性别匹配的对照行基因分型。
  • 利用公共临床基因组数据库(AMP-PD、GP2、100 000 Genomes Project)和德国蒂宾根大学私人临床诊断数据库行病例对照关联分析验证。
  • 行体外研究探究蛋白相互作用和酶活性。

主要发现

  • 2010年6月1日至2017年5月31日,130例先证者(女性47例[36%],男性83例[64%];平均年龄72.7岁[SD 11.7,范围38-96];109例欧洲白人、18例北非、2例东亚、1例西班牙裔)行全外显子测序。
  • 在RAB GTP酶基因中鉴定出15个变异,其中RAB32 c.213C>G(Ser71Arg)在三个家系(9例患者)中与常染色体显性帕金森病共分离(非参数连锁Z评分=1.95;p=0.03)。
  • 对2604例无关帕金森病患者和344例匹配对照行基因分型,另发现来自五个国家(加拿大、意大利、波兰、土耳其、突尼斯)的5例携带RAB32变异。
  • 数据库检索纳入6043例帕金森病患者和62 549例对照,另发现来自四个国家(加拿大、德国、英国、美国)的8例携带RAB32变异。
  • 总体RAB32 c.213C>G(Ser71Arg)与帕金森病的关联显著(OR 13.17,95%CI 2.15-87.23;p=0.0055;I²=99.96%)。

临床怎么用

  • 原文结论指出,未来转化研究应考虑这一共同病因,同时需评估RAB32 Ser71Arg的全球流行病学以指导遗传咨询。

局限性

  • 原文结论指出RAB32 Ser71Arg的全球流行病学仍需评估。
  • 原文报告异质性I²=99.96%。
  • 原文指出外显率不完全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Parkinson's disease is a progressive neurodegenerative disorder with multifactorial causes, among which genetic risk factors play a part. The RAB GTPases are regulators and substrates of LRRK2, and variants in the LRRK2 gene are important risk factors for Parkinson's disease. We aimed to explore genetic variability in RAB GTPases within cases of familial Parkinson's disease. METHODS: We did whole-exome sequencing in probands from families in Canada and Tunisia with Parkinson's disease without a genetic cause, who were recruited from the Centre for Applied Neurogenetics (Vancouver, BC, Canada), an international consortium that includes people with Parkinson's disease from 36 sites in 24 countries. 61 RAB GTPases were genetically screened, and candidate variants were genotyped in relatives of the probands to assess disease segregation by linkage analysis. Genotyping was also done to assess variant frequencies in individuals with idiopathic Parkinson's disease and controls, matched for age and sex, who were also from the Centre for Applied Neurogenetics but unrelated to the probands or each other. All participants were aged 18 years or older. The sequencing and genotyping findings were validated by case-control association analyses using bioinformatic data obtained from publicly available clinicogenomic databases (AMP-PD, GP2, and 100 000 Genomes Project) and a private German clinical diagnostic database (University of Tübingen). Clinical and pathological findings were summarised and haplotypes were determined. In-vitro studies were done to investigate protein interactions and enzyme activities. FINDINGS: Between June 1, 2010, and May 31, 2017, 130 probands from Canada and Tunisia (47 [36%] female and 83 [64%] male; mean age 72·7 years [SD 11·7; range 38-96]; 109 White European ancestry, 18 north African, two east Asian, and one Hispanic] underwent whole-exome sequencing. 15 variants in RAB GTPase genes were identified, of which the RAB32 variant c.213C>G (Ser71Arg) cosegregated with autosomal dominant Parkinson's disease in three families (nine affected individuals; non-parametric linkage Z score=1·95; p=0·03). 2604 unrelated individuals with Parkinson's disease and 344 matched controls were additionally genotyped, and five more people originating from five countries (Canada, Italy, Poland, Turkey, and Tunisia) were identified with the RAB32 variant. From the database searches, in which 6043 individuals with Parkinson's disease and 62 549 controls were included, another eight individuals were identified with the RAB32 variant from four countries (Canada, Germany, UK, and USA). Overall, the association of RAB32 c.213C>G (Ser71Arg) with Parkinson's disease was significant (odds ratio [OR] 13·17, 95% CI 2·15-87·23; p=0·0055; I2=99·96%). In the people who had the variant, Parkinson's disease presented at age 54·6 years (SD 12·75, range 31-81, n=16), and two-thirds had a family history of parkinsonism. RAB32 Ser71Arg heterozygotes shared a common haplotype, although penetrance was incomplete. Findings in one individual at autopsy showed sparse neurofibrillary tangle pathology in the midbrain and thalamus, without Lewy body pathology. In functional studies, RAB32 Arg71 activated LRRK2 kinase to a level greater than RAB32 Ser71. INTERPRETATION: RAB32 Ser71Arg is a novel genetic risk factor for Parkinson's disease, with reduced penetrance. The variant was found in individuals with Parkinson's disease from multiple ethnic groups, with the same haplotype. In-vitro assays show that RAB32 Arg71 activates LRRK2 kinase, which indicates that genetically distinct causes of familial parkinsonism share the same mechanism. The discovery of RAB32 Ser71Arg also suggests several genetically inherited causes of Parkinson's disease originated to control intracellular immunity. This shared aetiology should be considered in future translational research, while the global epidemiology of RAB32 Ser71Arg needs to be assessed to inform genetic counselling. FUNDING: National Institutes of Health, the Canada Excellence Research Chairs program, Aligning Science Across Parkinson's, the Michael J Fox Foundation for Parkinson's Research, and the UK Medical Research Council.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Gustavsson EK, Follett J, Trinh J, et al. RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses. Lancet Neurol. 2024. PMID: 38614108. doi:10.1016/S1474-4422(24)00121-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。